Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mapping the plasma proteomic architecture of systemic lupus erythematosus
Geoffrey H.D. Leung, Charlotte Bottomley, Norzawani Buang, Robert T. Maughan, Benjamin J. Whittle, Boroumand Zeidaabadi, Yun-Ju Huang, Tabitha Turner-Stokes, Marie Condon, Liz Lightstone, Tom Cairns, Marina Botto, Matthew C. Pickering, James E. Peters
Geoffrey H.D. Leung, Charlotte Bottomley, Norzawani Buang, Robert T. Maughan, Benjamin J. Whittle, Boroumand Zeidaabadi, Yun-Ju Huang, Tabitha Turner-Stokes, Marie Condon, Liz Lightstone, Tom Cairns, Marina Botto, Matthew C. Pickering, James E. Peters
View: Text | PDF
Research Article Clinical Research Inflammation

Mapping the plasma proteomic architecture of systemic lupus erythematosus

  • Text
  • PDF
Abstract

Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease, yet the molecular basis underlying this variability remains incompletely understood. We profiled the plasma proteome in 260 SLE patients and 86 healthy volunteers (HVs) using the SomaScan v4.1 platform, quantifying 7,288 analytes corresponding to 6,595 unique proteins. We identified 215 proteins that were robustly differentially abundant between SLE patients and HVs in both discovery (n = 207 SLE, n = 45 HVs) and validation sets (n = 53 SLE, n = 41 HVs). Within-cases analyses identified 421 proteins associated with disease activity. Network-based clustering delineated correlated protein modules, including an interferon-associated (IFN-associated) module and a kidney-associated module. Autoantibody-stratified analyses further uncovered distinct proteomic endotypes; positivity for antibodies targeting RNA-binding proteins (anti-Sm, anti–Ro-60, anti-RNP68, anti–RNP-A) was associated with increased IFN-stimulated protein levels (e.g., MX1, ISG15, and CXCL10), independent of disease activity. Anti-Sm, anti–RNP-A, and anti-Ro52 antibodies were associated with reduced plasma levels of their respective autoantigens. Anti-dsDNA antibodies were associated with elevated levels of CD40 ligand (CD40LG) and the neutrophil protease, proteinase-3. Moreover, we identified an association between CD40LG and disease activity specific to the anti-dsDNA–positive subgroup. Together, these data define plasma protein signatures of SLE and disease activity, highlight autoantibody-specific molecular phenotypes, and provide a basis for precision medicine.

Authors

Geoffrey H.D. Leung, Charlotte Bottomley, Norzawani Buang, Robert T. Maughan, Benjamin J. Whittle, Boroumand Zeidaabadi, Yun-Ju Huang, Tabitha Turner-Stokes, Marie Condon, Liz Lightstone, Tom Cairns, Marina Botto, Matthew C. Pickering, James E. Peters

×

Figure 2

Proteins associated with SLE disease activity.

Options: View larger image (or click on image) Download as PowerPoint
Proteins associated with SLE disease activity.
n = 260 SLE samples. (A) ...
n = 260 SLE samples. (A) Volcano plot. Linear gradient shows the magnitude and direction of change in the protein level with increasing disease activity. Dotted line = 5% FDR. Each point represents a protein. Red, significant positive association with active disease; blue, negative association; gray, non-significant. (B) Examples of disease activity–associated complement-related, IFN pathway, and immune signaling proteins. LG, linear gradient. Unique SOMAmer identifiers for displayed proteins where the SomaScan has more than 1 SOMAmer are B2M (seq.3485.28), IFN-α4 (IFNA4, seq.15405.23), IFN-γ (IFNG, seq.2989.17), TNFRSF1B (seq.3152.57), and VCAM1 (seq.2967.8). (C) Disease activity–associated proteins correlated with IFNL1. For clarity of visualization, only the proteins associated with disease activity at 1% FDR are displayed. A detailed list of proteins correlated with IFNL1 is provided in Supplemental Data 9. Edges represent pairwise protein correlations with |Pearson’s r| > 0.6. Node size, color, and edge thickness indicate the strength of correlation (Pearson’s r) with IFNL1. Edge color denotes correlation direction: blue for negative and red for positive. (D) Heatmap of significant (FDR < 0.05) disease activity–associated proteins in the KEGG “cytokine-cytokine receptor interaction” pathway. Protein levels were adjusted for sex and batch. PBH, Benjamini-Hochberg–corrected P value.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts